- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Cancer Screening May Be Overdone in Older Adults
More than half of surveyed seniors reported that their physicians continue to recommend cancer screening, despite ambiguity about its value for men and women over age 75, according to data analysis of a nationwide sample.
Among adults between the ages of 75 and 79, 57% were screened for colorectal cancer, 62% for breast, 53% for cervical, and 56% for prostate cancers, according to Keith M. Bellizzi, PhD, MPH, from the University of Connecticut in Storrs, and colleagues. In the group that was 80 years or older, rates varied from a low of 38% for cervical cancer screening to a high of 50% for breast cancers, they reported in the December 12 Archives of Internal Medicine.
Screening behaviors were examined according to the U.S Preventive Services Task Force recommendations.
They found that education and physician recommendations had higher predictive values for screening in those older than 75.
Read the full article at: http://www.medpagetoday.com/Geriatrics/GeneralGeriatrics/30193
Source: MedPage Today
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
